


In the News: Congratulations to the following awardees!



Chang-Xing Ma, Associate Professor of Biostatistics, is Co-I on a continuation award (PI: John Canty, Medicine) from the National Heart, Lung, and Blood Institute/NIH for the project entitled *PAREPET II_Prediction of ARhythmic Events with Positron Emission Tomography II*. The study will continue to collect preliminary data for a prospective trial to test whether primary prevention implantable cardiac defibrillator can be safely withheld in patients predicted to be at very low risk of sudden cardiac arrest.



Kimberly Naus, Director of CAT Clients Services, received a continuation of the award from the NYS Justice Center for the Protection of People with Special Needs entitled, *Technology-Related Assistance for Individuals with Disabilities (TRAID) Program*. The TRAIID program helps people with disabilities access and acquire assistive technology. Consumers are able to use devices on a trial basis to determine the usefulness and need prior to purchase.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, received a new award from Roche Molecular Systems for the research project entitled, *Evaluation and Implementation of a Novel Digital Solution for Multidisciplinary Tumor Boards (MTBs): An MTB Quality Improvement Feasibility/Pilot Study Evaluating Team Decision-Making*. This project will evaluate the feasibility of the implementation and impact of NAVIFY on MTBs quality and functioning.

Dr. Noyes also is Curriculum Director on a continuation award from the National Heart, Lung, and Blood Institute/NIH (PIs: Ranjit Singh and John Canty, Medicine) for the project entitled, *UB Clinical Scholar Program in Implementation Science to Achieve Triple Aims*. The program trains and prepares clinician scientists for academic leadership and independent research careers in dissemination and implementation science related to heart, lung, blood, and sleep disorders with associated risk factors and complexities.



Gregory Wilding, Professor and Chair of Biostatistics, received a new award from the National Institute of Child Health & Human Development/NIH (PI: Patricia Logan-Greene, School of Social Work) for the project entitled, *Neglect, Poverty, and Family Services: A Longitudinal Perspective on Child Wellbeing*. This study will utilize data from the LONGSCAN study, a prospective study on child maltreatment, to examine the longitudinal effects of neglect (specifically the dimensions of failure to provide and lack of supervision) and its co-occurrence with poverty.

In This Issue

In the News: Congratulations to the Following Awardees!	1
Grant Clinic.....	2
NIH Funding Opportunities	
Request for Applications (RFA)	8
Program Announcements Reviews in an Institute (PAR)	13
Program Announcements (PA)	21
Individual Actions for Sustainability	23

GRANT CLINIC

GENERAL NOTICE

A new Research Space/Venue Questionnaire is now available on the [SPHHP website](#).

Investigators who are planning to submit proposals, please complete both the [RAS Questionnaire](#) and [Research Venue/Space Questionnaire](#).

[2021 NIH Virtual Seminar on Grants Administration and Program Funding](#)

If you are an administrator, researcher, early-stage investigator, graduate student, or anyone new to working with the NIH grants process, then this seminar is designed specifically for you. More experienced? Attend our policy updates and check out our case study series. **Monday, November 1 – Thursday, November 4, 2021** [Free Registration](#)

NIH Applications: Page limits on attachments

<https://nexus.od.nih.gov/all/2021/06/29/does-every-attachment-in-a-grant-application-have-a-page-limit/>

NIH Applications: Creating system and people-friendly pdfs

<https://nexus.od.nih.gov/all/2021/06/30/creating-people-and-system-friendly-pdf-attachments/>

[NOT-OD-21-169](#)

New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022

See [High-level Summary of Form Changes in FORMS-G Application Packages](#) for a full list of form changes. Applicants must use FORMS-G application packages for due dates on or after January 25, 2022 and must use FORMS-F application packages for due dates on or before January 24, 2022. Applications submitted using the wrong forms for their intended due date may be withdrawn and removed from funding consideration.

[NIH Loan Repayment Programs \(LRP\) Application Cycle Opened on September 1](#)

The LRPs are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. Awardees can receive up to **\$100,000** of qualified educational debt repayment with a two-year contract. The LRP application cycle will close on **November 18th**. Be sure to visit www.lrp.nih.gov to take advantage of all of the available resources, and to learn more about eligibility requirements, application dates, and all of the benefits of the NIH LRPs.

[NOT-OD-21-073](#)

Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021

Please check the Notice for the Specific changes. A full copy of the updated Biosketch instructions can be found [here](#). Use of the updated format pages will be required for applications and Research Performance Progress Reports (RPPRs) submitted for due dates on or after May 25, 2021. During the transition to the new Biosketch format, NIH will not withdraw applications that include the previous Biosketch format. Beginning with applications submitted on or after January 25, 2022, failure to follow the appropriate Biosketch format may cause NIH to withdraw your application from consideration.

REQUESTS FOR INFORMATION

[NOT-OD-21-183](#)

Request for Information (RFI): Research Opportunities to End Hunger, Food and Nutrition Insecurity.

This Request for Information (RFI) invites input on the approaches NIH can take to address hunger, food insecurity and nutrition insecurity through innovative and multidisciplinary research. Food security has been defined as having the availability of sufficient food, compared to nutrition security, ensuring that food quality meets human nutrient needs.[1] Several areas of investigation could potentially reveal strategies to advance nutrition science, improve coordination of federal food and nutrition policy, along with strategies and tactics to integrate nutrition with healthcare. Responses will be accepted through **November 1, 2021**.

[NOT-AA-21-042](#)

Request for Information (RFI): Unhealthy Alcohol Use in Active-Duty Military

The Military Operational Medicine Research Program (MOMRP), as part of the U.S. Army Medical Research and Development Command (USAMRDC), and the NIAAA are requesting information from the broad community of alcohol researchers, clinicians, individual Service Members, and advocates to help identify the most important research questions that may help prioritize future alcohol research investments. The [MOMRP](#) and the [NIAAA](#) missions and strategic plans provide the current research focus areas for the respective organizations. To ensure full consideration, responses must be received by **December 1, 2021**.

[NOT-OD-21-161](#)

Request for Information (RFI) on Clarifying the Reporting Requirements for Departures from the Guide for the Care and Use of Laboratory Animals

Through this Request for Information (RFI), the NIH Office of Laboratory Animal Welfare ([OLAW](#)) is seeking input on clarifying guidance to Assured institutions regarding the Institutional Animal Care and Use Committee (IACUC) reporting requirements for departures from the *Guide for the Care and Use of Laboratory Animals (Guide)*. Comments must be received on or before **November 1, 2021, at 11:59 PM ET**.

REQUESTS FOR PROPOSAL

[NOT-OD-21-139](#) Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

[NOT-OD-21-140](#) Extramural Loan Repayment Program for Pediatric Research (LRP-PR)

[NOT-OD-21-141](#) Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)

[NOT-OD-21-142](#) Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)

[NOT-OD21-143](#) Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR)

These Notices provides program-specific information for a new Extramural Loan Repayment Program subcategory called the Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH). The NIH Loan Repayment Programs (LRPs) are a set of programs

established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. Additional detailed information about each LRP is provided at www.lrp.nih.gov/eligibility-programs and www.lrp.nih.gov/apply. The deadline for the applications period will be November 18, 2021

NOTICE OF INTENT TO PUBLISH

NOT-HS-21-019

Notice of Intent to Publish Funding Announcement for Strategies to Implement Evidence-based Care to Reduce High Burden Racial and Ethnic Disparities

The Agency for Healthcare Research and Quality's (AHRQ) intends to publish a Notice of Funding Opportunity (NOFO) to disseminate and implement patient-centered outcomes research (PCOR) findings that have been found to be the most impactful in reducing specific healthcare disparities. Interventions must be focused specifically on the goal of reducing disparities by wide-scale implementation of evidence-based care.

NOT-NS-22-004

Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer's Disease and Alzheimer's Disease Related Dementias (R01 Clinical Trial Not Allowed)

The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA) intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on the clinical relevance of the linkage between environmental toxicant exposures and Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). The FOA is expected to be published in Winter 2022 with an expected application due date in Spring 2022.

NOTICE OF CHANGES TO FUNDING OPPORTUNITIES

NOT-DA-22-015

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately in NOT-MD-21-008, Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities".

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

NOT-DA-21-020

Evaluation of Sex Differences on HIV-associated Comorbidities in the Context of Stimulant Use

The goal of this Notice is to encourage applications focusing on the understanding of the biological basis of sex differences in HIV neuropathogenesis and the comorbidity of HIV with misuse of stimulants, including amphetamine, methamphetamine, cocaine, and nicotine. Studies at single cell and CNS circuits levels and in live behaving animals are encouraged. Check the FOA for a list of the announcements. **Applicants must include "NOT-DA-21-020" in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2025

[NOT-DA-21-064](#)

International Research Collaboration on Drug Abuse and Addiction Research

The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science. Check the FOA for a list of the announcements. **Applicants must include “NOT-DA-21-064” in box 4B of the SF424 R&R form.** This NOSI expires on September 08, 2024.

[NOT-OD-21-127](#)

Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects

The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. Check the FOA for a list of the announcements. **Applicants must include “NOT-IC-19-XXX” in box 4B of the SF424 R&R form.**

[NOT-CA-21-074](#)

Early-life Factors and Cancer Development Later in Life

This NOSI seeks to further support research on early-life factors and cancer development later in life. Studies proposed in response to this NOSI should focus on human studies, but may incorporate research using animal models, especially in elucidating mechanisms relevant in humans. **Applicants must include “NOT-CA-21-074” in box 4B of the SF424 R&R form.** This NOSI will expire on March 08, 2024.

[NOT-CA-21-085](#)

New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer

This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer. **Applicants must include “NOT-CA-21-085” in box 4B of the SF424 R&R form.**

[NOT-HD-21-027](#)

Navigating Pediatric to Adult Health Care: Lost in Transition

The purpose of this NOSI is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT. **Applicants must include “NOT-HD-21-027” in box 4B of the SF424 R&R form.**

[NOT-AI-21-057](#)

HIV/AIDS in the Era of COVID-19: When Pandemics Collide

This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the coronavirus disease 2019 (COVID-19) pandemic. Submit applications for this initiative using [PA-20-185](#) & [PA-20-195](#). **Applicants must include “NOT-AI-21-057” in box 4B of the SF424 R&R form.**

[NOT-AA-21-028](#)

Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes

This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes. **Applicants must include “NOT-AA-21-028” in box 4B of the SF424 R&R form.**

[NOT-DA-21-012](#)

Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence

The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. **Applicants must include “NOT-DA-21-012” in box 4B of the SF424 R&R form.**

[NOT-CA-21-071](#)

Expanding Cancer Control Research in Persistent Poverty Areas

The purpose of this Notice is to inform potential applicants about the National Cancer Institute (NCI)'s special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas. **Applicants must include “NOT-CA-21-071” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-DA-21-003](#)

Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder

NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged. **Applicants must include “NOT-DA-21-003” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-AG-21-015](#)

Ageing-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

This Notice of Special Interest (NOSI) is to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. **Applicants must include “NOT-AG-21-015” in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-CA-21-031](#)

Understanding the Effects of Cancer and Cancer Treatment on Aging Trajectories and Aging Outcomes

The purpose of this Notice of Special Interest is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. Investigations in understudied populations, including those that are medically underserved, are encouraged. This notice applies to due dates on or after *March 8, 2021*, and subsequent receipt dates through January 7, 2024. **Applicants must include “NOT-CA-21-031” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2024.

[NOT-DA-21-011](#)

Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

The purpose of this notice is to communicate NIDA’s interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.** This Notice is a reissuance of [NOT-DA-20-084](#). Research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection are interested. **Applicants must include “NOT-DA-21-011” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-DA-21-017](#)

Medical Consequences of Smoking & Vaping Drugs of Abuse in Individuals with HIV and COVID-19

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. **Applicants must include “NOT-DA-21-017” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-MD-21-008](#)

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include “NOT-MD-21-008” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2022.

[NOT-CA-21-008](#)

Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

Through funds available from the [Cancer Moonshot Initiative](#), and pursuant to the National Cancer Institute’s (NCI’s) interest in advancing data visualization tools and methods for cancer research, applications are invited, through [PA-20-272](#) in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more explorable and interpretable by the broader cancer research community. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “PA-20-272” in box 4B of the SF424 R&R form.** Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022.

[NOT-OD-21-087](#)

Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being

The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults,

persons with medical/behavioral health conditions, and persons with disabilities). **Applicants must include “NOT-OD-21-087” in box 4B of the SF424 R&R form.** This NOSI will expire on February 16, 2024.

[NOT-OD-21-100](#)

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

The objective of this NOSI is to encourage research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. **Applicants must include “NOT-OD-21-100” in box 4B of the SF424 R&R form.** This NOSI will expire on June 08, 2024.

[NOT-CA-21-062](#)

National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) are issuing this Notice of Special Interest (NOSI) to encourage SBIR/STTR grant applications from small business concerns (SBCs) in response to SBIR/STTR Omnibus Solicitations proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. **Applicants must include “NOT-CA-21-062” in box 4B of the SF424 R&R form.** This NOSI will expire on September 07, 2024.

[NOT-OD-21-150](#)

Interventions Designed to Change the Culture to Mitigate or Eliminate Sexual Harassment in the Biomedical Research Enterprise

The purpose of this Notice is to inform potential applicants of the NIH’s interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the [Anti-Sexual Harassment](#) policy statements released by NIH as well as recommendations made in the December 2019 Report from the [Working Group to the Advisory Committee to the NIH Director \(ACD\) on Changing the Culture to End Sexual Harassment](#), which were endorsed by the ACD. **Applicants must include “PAR-21-269” in box 4B of the SF424 R&R form.** This NOSI will expire on October 14, 2023.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

NOVEMBER DUE DATES

[RFA-NS-22-009](#) (U01 Clinical Trial Required)

Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials

Applications must propose pragmatic clinical trials to test paradigms to detect cognitive impairment, including dementia, with adequate power in up to 3 populations including at least two specified populations that experience health disparities. Clinical paradigms proposed for pragmatic clinical trials should have rigorous supporting preliminary data and utilize tools that are simple to use, standardized, integrated into the electronic medical record (EMR) workflow, and ideally take five minutes or less to administer in a primary care clinical setting. **Application Due Date:** November 10, 2021

[RFA-ES-21-008](#) (UG3/UH3 Clinical Trial Optional)

[RFA-ES-21-009](#) (R41/R42 Clinical Trial Not Allowed)

Innovative Approaches for Improving Environmental Health Literacy

The purpose of the FOAs is to engage the small business community to work with environmental health science researchers with an expertise in community engagement and/or research translation, and

educators to develop tools, activities, or materials to build environmental health literacy for students, health professionals, and the general public. Examples of successful projects can be found on our Science Education page (<https://www.niehs.nih.gov/research/supported/translational/ehsic/index.cfm#a844570>)

Application Due Date: November 10,2021

[RFA-DA-22-022](#) (UG3/UH3 Clinical Trial Optional)

Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose

The purpose of this UG3/UH3 Phased Innovation Award Funding Opportunity Announcement is to support research to understand and respond to the new challenges in treating drug addiction and overdose, introduced by the presence of fentanyl and its analogs (fentanyls) in illicit drug supplies. Applications should focus on understanding and treating opioid and polydrug use disorders (including overdose), wherein fentanyls are a major contributor and their presence has altered previous estimations of the scope, impact and treatment of the problem. **Application Due Date:** November 11,2021

[RFA-DA-22-020](#) (UE5 Clinical Trial Not Allowed)

Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers

This FOA seeks applications to develop a customized curriculum and implement education programs/short courses in biomedical entrepreneurship, innovation and biomedical product development, specifically targeting scientists working in the field of drug addiction research.

Application Due Date: November 18,2021

[RFA-DA-22-017](#) (R01 - Clinical Trial Optional)

PrEP for HIV Prevention among Substance Using Populations

NIDA is interested in research that addresses research gaps related to PrEP and its use among people who use drugs (PWUD), with the goals of improving PrEP uptake, adherence and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. This RFA is restricted to projects conducted in the United States. Applications are encouraged that propose research in states and counties identified in the US Government's Ending the HIV Epidemic (EHE) initiative.

Application Due Date: November 12,2021

[RFA-AA-21-005](#) (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Date:** November 15,2021

[RFA-AA-21-006](#) (P60 Clinical trial Optional)

Comprehensive Alcohol Research Centers

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Date:** November 15,2021

[RFA-CA-21-013](#) (R21 Clinical Trial Optional)

[RFA-CA-21-014](#) (U01 Clinical Trial Optional)

[RFA-CA-21-015](#) (U24 Clinical Trial Optional)

[RFA-CA-21-016](#) (U24 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

The purpose of FOA is to invite applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined as initial tool development or the significant modification of existing tools for new applications. **Application Due Date:** November 17, 2021

[RFA-HD-22-009 \(P01 Clinical Trial Optional\)](#)

Impact of Technology and Digital Media (TDM) Exposure/Usage on Child and Adolescent Development

This funding opportunity announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs examining the pathways by which technology and digital media (TDM) exposure and usage impact developmental trajectories and health outcomes in early childhood (ages birth-8) and adolescence (ages 9-17). **Application Due Date:** November 29, 2021

DECEMBER DUE DATES

[RFA-AI-21-058 \(R01 Clinical Trial Optional\)](#)

American Women: Assessing Risk Epidemiologically

This Funding Opportunity Announcement (FOA) will support research that combines epidemiologic methods, digital technology, and data science approaches to better understand HIV prevention, transmission, and early care-cascade points for women living in the US. Applications must: 1) determine the best ways to identify, enroll, and retain cohorts of women living in the United States (US) who are behaviorally vulnerable to HIV; and 2) develop a knowledgebase comprised of cohort data from women augmented with other data sources including big data sources. **Application Due Date:** December 09, 2021

[RFA-CA-21-056 \(U01 Clinical Trial Optional\)](#)

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries

This FOA solicits applications that will identify, understand, and develop strategies to address barriers to the adoption, integration, and sustainability of evidence-based cancer control interventions among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control for PLWH worldwide. Responsive applications should include multi-disciplinary teams of researchers with expertise in HIV, cancer, and implementation science to address the cancer control needs of PLWH populations specific to the proposed LMIC context.

Application Due Date: December 15, 2021

FEBRUARY 2022 DUE DATES

[RFA-DA-22-018 \(R41/R42 CLINICAL TRIAL NOT ALLOWED\)](#)

[RFA-DA-22-023 \(R43/R44 CLINICAL TRIAL NOT ALLOWED\)](#)

Advancing Validated Drug Targets for Substance Use Disorders

This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to continue research projects with robustly validated targets for Substance Use Disorders (SUDs). This FOA will provide funding for projects entering at either assay development (AD), lead identification (LI), lead optimization (LO), or preclinical development (PCD) stages to allow for the ultimate goal of successfully completing Investigational New Drug-enabling activities.

Application Due Date: February 18, 2022

[RFA-DA-22-028 \(R01 - Clinical Trial Optional\)](#)

[RFA-DA-22-039 \(R21 - Clinical Trial Optional\)](#)

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products

The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ^9 -tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. **Application Due Date:** February 09, 2022

MARCH 2022 DUE DATES

[RFA-DK-21-018 \(R01 Clinical Trial Required\)](#)

Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus

The purpose of this FOA is to support pilot and feasibility trials of interventions designed to improve technology adoption in individuals from underrepresented backgrounds with type 1 diabetes mellitus (T1D). Through successful execution, these pilot and feasibility trials should provide feasibility data for larger, pragmatic trials with the overarching goal of reducing health disparity in T1D through improving technology usage in individuals from minority racial and ethnic backgrounds. **Application Due Date:** March 03, 2022

MULTIPLE DUE DATES

[RFA-DA-22-040 \(R01 Clinical Trial Optional\)](#)

High Priority HIV and Substance Use Research

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.

Application Due Dates: Monthly due dates; please refer to the RFA.

[RFA-HL-22-010 \(K01 Independent Clinical Trial Required\)](#)

[RFA-HL-22-011 \(K01 Independent Clinical Trial Not Allowed\)](#)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 14, 2021; February 11, 2022; October 13, 2022; February 14, 2023; October 13, 2023; February 13, 2024

[RFA-HL-23-004 \(R35 Clinical Trial Optional\)](#)

NHLBI Outstanding Investigator Award (OIA)

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2022; February 15, 2023; February 15, 2024

[RFA-HL-23-005 \(R35 Clinical Trial Optional\)](#)

NHLBI Emerging Investigator Award (EIA)

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA will support the research program of NHLBI-funded investigators for up to seven years.

Application Due Dates: February 15, 2022; February 15, 2023; February 15, 2024

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Application Due Dates: January 6, 2022; April 6, 2022; September 8, 2022

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date. **Application Due Dates:** October 22, 2021; October 21, 2022

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: February 10, 2022; June 8, 2022; October 11, 2022

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree. **Application Due Date:** July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Date: July 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Date:** September 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. **Application Due Dates:** Monthly due dates; please refer to the RFA.

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES. **Application Due Dates:** June 22, 2022; June 22, 2023.

[RFA-AI-21-023](#) (R01 Clinical Trial Optional)

Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE)

The purpose of FOA is to support applications that address the RESPOND pillar of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S. **Application Receipt Dates:** Multiple dates, see announcement.

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-21-303](#) (R21/R33 - Clinical Trial Optional)

Mobile Health: Technology and Outcomes in Low- and Middle-Income Countries

The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs.

Application Due Dates: November 05, 2021; November 05, 2022

[PAR-21-281](#) (R01 Clinical Trials Not Allowed)

Dyadic Interpersonal Processes and Biopsychosocial Outcomes

This funding opportunity announcement (FOA) invites basic and/or methodological research projects that seek to illuminate or measure independent and interdependent health-related effects within dyads. For the purpose of this FOA, a *dyad* is a unit of two individuals whose interactions and influences on one another are nested within larger social contexts and networks. Both animal and human subjects research projects are welcome. **Application Due Dates:** February 05, 2022; February 05, 2023

[PAR-21-287](#) (R01 Clinical Trial Optional)

Effectiveness of School-Based Health Centers to Advance Health Equity

The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth).

Application Due Dates: [Standard dates](#) apply.

[PAR-21-286 \(R50 Clinical Trial Not Allowed\)](#)

NCI Research Specialist (Core-based Scientist) Award

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise.

Application Due Date: March 17, 2022.

[PAR-21-168 \(R25\) Clinical Trial Not Allowed](#)

Summer Research Education Experience Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. R25 programs that propose at least 8 weeks, but fewer than 15 weeks, of full-time research experiences during the summer may request continued part-time support for the participants to work on their research projects during the school year, up to the equivalent of a total of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Applications that demonstrate the potential to impact students and teachers from diverse backgrounds are particularly encouraged.

Application Due Dates: March 17, 2022; March 17, 2023; March 19, 2024

[PAR-20-236\(R25\) Clinical Trials Not Allowed](#)

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** November 15, 2021; March 15, 2022; August 10, 2022; November 15, 2022; March 15, 2023; August 10, 2023; November 15, 2023

[PAR-20-310 \(R01\) Clinical Trial Optional](#)

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged.

Application Due Dates: November 17, 2021; March 17, 2022; November 17, 2022; February 17, 2023

[PAR-20-302\(R01\)](#)

[PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA.

Application Due Dates: December 7, 2021; December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: January 7, 2022; May 7, 2022; January 7, 2023

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with [PATH Study objectives](#) and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens. **Application Due Dates:** October 29, 2021; April 29, 2022; October 31, 2022; April 28, 2023; October 31, 2023

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2022; August 25, 2023

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH)

definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; **Application Due Dates:** Standard dates apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions. **Application Due Dates:** Standard dates apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required)

Stephen I. Katz Early Stage Investigator Research Project Grant

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023

[PAR-21-072](#) (R24 Clinical Trial Not Allowed)

NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. **Application Due Dates:** Standard dates apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). **Application Due Dates:** Standard dates apply

[PAR-20-315](#) (R00 Clinical Trial Optional)

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Due Dates: Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. **Application Due Dates:** Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes. **Application Due Dates:** Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies

that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. **Application Due Dates:** February 17, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 17, 2023

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. **Application Due Dates:** February 17, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 17, 2023

[PAR-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#). **Application Due Dates:** Standard dates apply.

[PAR-21-299](#) (K08 Clinical Trial Required)

[PAR-21-300](#) (K08 - Independent Clinical Trial Not Allowed)

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity

This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. **Application Due Dates:** Standard dates apply.

[PAR-21-170](#) (K01 Independent Basic Experimental Studies with Humans Required)

[PAR-21-171](#) (K01 Clinical Trial Required)

[PAR-21-172](#) (K01 Clinical Trial Not Allowed)

Transition to Independent Environmental Health Research (TIEHR) Career Award

The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. **Application Due Dates:** Standard dates apply.

[PAR-21-301](#) (K22 Independent Clinical Trial Not Allowed)

[PAR-21-302](#) (K22 Clinical Trial Required)

NCI Transition Career Development Award to Promote Diversity

This Funding Opportunity Announcement (FOA) is a continuation of the NCI Transition Career Development Award to Promote Diversity (K22) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. **Application Due Dates:** Standard dates apply.

[PAR-21-330](#) (U01 Clinical Trial Not Allowed)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research

The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-270](#) (R03 Clinical Trial Optional)

AIDS-Science Track Award for Research Transition

This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-173](#) (R16 - Clinical Trial Not Allowed)

Support for Research Excellence – First Independent Research (SuRE-First) Award

The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants. Since the SuRE-First Award is structured to best support a single PD/PI, multiple PD(s)/PI(s) are not allowed. PD(s)/PI(s) with similar or complementary research interests may apply separately. A PD/PI must have a full-time tenure-track (or equivalent) faculty appointment at the applicant institution and be eligible to apply for NIH research project grants.

Application Due Dates: Standard dates apply.

[PAR-21-271](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

[PAR-21-272](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)

[PAR-21-273](#) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))

[PAR-21-277](#) Institutionally Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)

Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIH MOSAIC UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on 1. *Courses for Skills Development*; 2. *Mentoring Activities*.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-278](#) (R25 Clinical Trial Not Allowed)

[PAR-21-279](#) (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program - Research Experiences

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on **Research Experiences**. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

[PAR-21-307](#) (R01 Clinical Trial Required)

Dementia Care and Caregiver Support Intervention Research

This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the [NIH Stage Model](#) to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-308](#) (R61/R33 – Clinical Trial Required)

Pragmatic Trials for Dementia Care and Caregiver Support

This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the [NIH Stage Model](#) to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer's disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-306](#) (R50 Clinical Trial Not Allowed)

NCI Research Specialist (Clinician Scientist) Award

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-183](#) (UG3/UH3 Clinical Trial optional)

Developing Digital Therapeutics for Substance Use Disorders

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-206](#) (R01 Clinical Trial Optional)

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-208](#) (R21 Clinical Trial Optional)

Cutting-Edge Basic Research Awards (CEBRA)

The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. The program supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-196](#) (R25 Independent Clinical Trial Not Allowed)
Innovative Programs to Enhance Research Training (IPERT)**

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs. this FOA will support creative educational activities with a primary focus on: ***Courses for Skills Development; Mentoring Activities***. **Application Due Dates:** October 14, 2022; October 13, 2023

[PAR-21-197](#) (UG3/UH3 Clinical Trial Required)

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years.

Application Due Dates: Multiple dates, see announcement.

[PAR-21-207](#) (R01 Clinical Trial Optional)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias

This FOA invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. **Application Due Dates:** Multiple dates, see announcement.

[PAR-21-250](#) (R21/R33 Clinical Trial Optional)

Mechanisms of Alcohol Tolerance

The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. **Application Due Dates:** Multiple dates, see announcement.

[NIH Funding Opportunities: Program Announcements \(PA\)](#)

The following opportunities have standard due dates unless noted otherwise:

[PA-21-262](#)

PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

Expiration Date: April 06, 2022

[PA-21-261](#)

PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Expiration Date: April 06, 2022

[PA-21-260](#)

PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

Expiration Date: April 06, 2022

[PA-21-259](#)

PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Expiration Date: April 06, 2022

[PA-21-232](#)

Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

Expiration Date: September 08, 2024

[PA-21-180](#)

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

Expiration Date: May 08, 2024

[PA-21-205](#)

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

Expiration Date: May 08, 2024

[PA-21-164](#)

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)

Expiration Date: July 18, 2024

[PA-21-151](#)

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Expiration Date: January 08, 2024

[PA-21-071](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Expiration Date: May 8, 2023

[PA-20-272](#)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Expiration Date: July 24, 2023

[PA-21-110](#) Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

Expiration Date: May 08, 2024

Foundation Funding Opportunities

[Robert Wood Johnson Foundation](#)

Evidence for Action: Innovation Research to Advance Racial Equity

This funding is focused on studies about upstream causes of health inequities, such as the systems, structures, laws, policies, norms, and practices that determine the distribution of resources and opportunities, which in turn influence individuals' options and behaviors. Research should center on the needs and experiences of communities exhibiting the greatest health burdens and be motivated by real-world priorities. It should be able to inform a specific course of action and/or establish beneficial practices, not stop at characterizing or documenting the extent of a problem.

Applications are accepted on a rolling basis. Applicants will generally receive notice within six to nine weeks of applying as to whether they are invited to submit a full proposal. Full proposals will be due two months from the date of notification.

[Robert Wood Johnson Foundation](#)

Pioneering Ideas: Exploring the Future to Build a Culture of Health

We are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. **Applications are accepted throughout the year on a rolling basis.**

Individual Actions for Sustainability

“Eat less meat, purchase food and items produced locally whenever possible, and reduce the amount of food waste your household produces”.

- Susan Clark, assistant professor at UB's Department of Environment and Sustainability



Visit our website for more information about research sphhp.buffalo.edu/ras